Humacyte, Inc.

Quick facts

Phase 3 pipeline

• Human Acellular Vessel (HAV) · Cardiovascular
  Human Acellular Vessel (HAV) is a tissue-engineered vascular graft derived from human cells that provides a biocompatible alternative to synthetic or animal-derived vascular conduits for vascular reconstruction.

Phase 2 pipeline

• HAV implantation

Phase 1 pipeline

• HAVG

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Humacyte, Inc. portfolio CI brief
• Humacyte, Inc. pipeline updates RSS